Browse the evidence

SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease, independent of diabetes status.

Semaglutide may significantly lower the risk of cardiovascular events in at-risk populations.

Obesity is a significant modifiable risk factor for atrial fibrillation (AF).

Practitioners should focus on managing obesity to reduce the risk of AF.

GLP-1 agonists are approved for weight loss in addition to their original approval for type 2 diabetes.

Healthcare providers should consider GLP-1 agonists for patients needing weight loss support.

GLP-1-based therapies elicit a clinically significant reduction in body weight.

Practitioners can expect GLP-1 therapies to aid in weight loss for patients with type 2 diabetes or obesity.

Tirzepatide reduces appetite and aids in weight reduction management.

Tirzepatide may be effective for patients seeking weight loss.

Tirzepatide is the first dual receptor agonist incorporated into therapeutic recommendations for type 2 diabetes.

Tirzepatide should be considered as a treatment option for type 2 diabetes.

There is a greater emphasis on adjunct pharmacotherapy in the updated guideline, particularly with GLP-1-based agents for weight reduction and improvement of comorbidities.

Healthcare providers should integrate GLP-1-based pharmacotherapy into obesity management strategies.

Binge eating episodes and prevalence reduced following liraglutide and semaglutide.

Practitioners may find liraglutide and semaglutide effective in reducing binge eating behaviors in patients.

PAP+tirzepatide was associated with lower incident PH at 1 year (RR:0.27) and 3 years (RR:0.22), and lower mortality at 1 year (RR:0.14) and 3 years (RR:0.12).

Using tirzepatide in conjunction with PAP may provide superior benefits in reducing PH and mortality for obese patients with OSA.

Compared to PAP+semaglutide, PAP+tirzepatide showed lower incident PH at 1 year (RR:0.51) and 3 years (RR:0.42) and lower all-cause mortality at 1 year (RR:0.41) and 3 years (RR:0.33).

Tirzepatide may offer enhanced benefits over semaglutide for reducing PH and mortality in obese patients with OSA on PAP.

The GLP-1 receptor agonist Semaglutide and the GIPR/GLP-1R co-agonist Tirzepatide lead to a weight loss greater than 10%.

Practitioners can consider Semaglutide and Tirzepatide as effective options for weight management in patients with obesity and Type 2 diabetes.

GLP-1 agonists such as liraglutide and semaglutide are more efficacious than other approved drugs in weight management therapy.

Practitioners may consider GLP-1 agonists as a preferred option for weight management in diabetic patients.

Tirzepatide reduces fasting and postprandial glucose levels, food consumption, and body weight in people with type 2 diabetes.

Tirzepatide may be an effective treatment option for managing blood glucose and weight in type 2 diabetes patients.

Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight.

Practitioners may consider GLP-1 agonists and incretin multi-agonists as effective options for weight management in obese patients.

GLP-1 based medications can achieve an average weight loss of 24%.

Practitioners can expect significant weight loss with GLP-1 medications.

GLP-1-agonists significantly reduce the risk of cardiovascular endpoints in patients with overweight or obesity without diabetes, with a Number Needed to Treat (NNT) of 44.

GLP-1-agonists may be considered for reducing cardiovascular risk in non-diabetic patients with obesity.

Incretin drug therapy can produce significant weight loss in properly selected individuals.

Clinicians should consider incretin therapy for weight loss in appropriately selected patients.

Bariatric surgery is the most effective treatment for obesity, yielding sustainable weight loss of about 20-30%.

Bariatric surgery should be considered for patients with obesity seeking significant weight loss.

GLP-1 receptor agonist semaglutide 2.4 mg and dual GLP-1 and GIP agonist tirzepatide have raised the bar for weight loss efficacy in obesity pharmacotherapies.

Clinicians should consider GLP-1 and GIP agonists as effective options for obesity treatment.

Combinations of GLP-1 RA, GIP, and glucagon RA (retatrutide) have shown weight loss efficacy approaching that of bariatric surgery.

Combination therapies may offer significant weight loss benefits similar to surgical options.

Second-generation drugs for obesity treatment can achieve weight loss of 15-25%, comparable to bariatric surgery.

Healthcare professionals can consider second-generation drugs as effective options for weight management in obese patients.

GLP-1 receptor agonists can achieve weight loss of 15-17% with a good safety profile.

GLP-1 receptor agonists are a viable treatment option for weight loss in obese patients.

Tirzepatide can achieve weight loss of up to 22.5% at the highest doses.

Tirzepatide represents a potent option for significant weight loss in obese patients.

Once-weekly GLP-1RA therapy can produce substantial weight loss over prolonged treatment (up to 23% at 72 weeks), alongside improvements in metabolic outcomes and reduced cardiometabolic risk.

GLP-1RA therapies can be effective for significant weight loss and improving metabolic health in obese patients.